The Role of Radiotherapy in Octogenarian Cancer Patients

The use of radiotherapy in oncology patients aged 80 years and older represents a significant clinical challenge due to the limited availability of prospective data and the under-representation of this age group in clinical trials. Most existing evidence originates from retrospective analyses of small patient cohorts. Radiotherapy remains a cornerstone of cancer treatment, providing both curative and palliative benefits. Technological advances, including intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT), have significantly improved treatment precision, reduced toxicity, and enabled the adoption of hypofractionated regimens. These shortened treatment schedules are particularly advantageous for older patients, reducing the burden of prolonged therapy while maintaining therapeutic efficacy. Comprehensive Geriatric Assessment (CGA) plays a crucial role in optimizing treatment decisions for octogenarian patients by addressing their clinical, functional, and psychosocial needs. However, the routine use of CGA remains limited due to logistical and time constraints. Despite these challenges, current evidence suggests that radiotherapy is generally well tolerated in this population, with acceptable toxicity profiles even among frail patients. As the global population of individuals aged 80 years and older continues to increase, the development of specific clinical guidelines tailored to this demographic has become essential. There is an urgent need for prospective studies providing robust evidence regarding the efficacy, safety, and tolerability of radiotherapy in older adults. This review aims to summarize the current state of knowledge on the role of radiotherapy in patients aged 80 years and older and to highlight the need for evidence-based, individualized oncologic care for this growing patient population.